autologous latent membrane protein 2-specific T-cell receptor-engineered T-cell therapy

Autologous latent membrane protein 2-specific T-cell receptor-engineered T-cell therapy is an adoptive cellular immunotherapy designed to target Epstein-Barr virus (EBV)-associated malignancies, such as nasopharyngeal carcinoma (NPC) and extranodal NK/T-cell lymphoma. The therapy involves isolating a patient's autologous T lymphocytes and genetically engineering them ex vivo to express a T-cell receptor (TCR) specific for the EBV latent membrane protein 2 (LMP2) antigen, typically presented in complex with specific HLA alleles (such as HLA-A2, HLA-A11, or HLA-A24). Once reinfused, these engineered TCR-T cells selectively recognize and eliminate LMP2-expressing tumor cells. Clinical development, including trials sponsored by Sun Yat-sen University and supported by TCRCure Biopharma, has evaluated this approach in patients with recurrent or metastatic nasopharyngeal carcinoma.

Other names

autologous LMP2-specific TCR-T cell therapyEBV TCR-T cellsLMP2 Antigen-specific TCR T cellsLMP-2 Antigen-specific TCR T cellsLMP 2 Antigen-specific TCR T cellsLMP2-specific T-cell receptor-engineered T-cell therapyLMP-2-specific T-cell receptor-engineered T-cell therapyLMP 2-specific T-cell receptor-engineered T-cell therapyLMP2-specific T-cell receptor-transduced autologous T lymphocytesLMP-2-specific T-cell receptor-transduced autologous T lymphocytesLMP 2-specific T-cell receptor-transduced autologous T lymphocytesLMP2-specific TCR-TLMP-2-specific TCR-TLMP 2-specific TCR-TLMP2-specific TCR-T cell therapyLMP-2-specific TCR-T cell therapyLMP 2-specific TCR-T cell therapy